Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Notes Payables: 2014-2020

Historic Notes Payables for Zevra Therapeutics (ZVRA) over the last 3 years, with Sep 2020 value amounting to $65.9 million.

  • Zevra Therapeutics' Notes Payables rose 881.24% to $65.9 million in Q3 2020 from the same period last year, while for Sep 2020 it was $65.9 million, marking a year-over-year increase of 881.24%. This contributed to the annual value of $7.0 million for FY2019, which is 109.45% up from last year.
  • According to the latest figures from Q3 2020, Zevra Therapeutics' Notes Payables is $65.9 million, which was down 2.01% from $67.3 million recorded in Q2 2020.
  • Zevra Therapeutics' Notes Payables' 5-year high stood at $68.6 million during Q1 2020, with a 5-year trough of $1.6 million in Q1 2016.
  • Over the past 3 years, Zevra Therapeutics' median Notes Payables value was $6.5 million (recorded in 2019), while the average stood at $22.0 million.
  • Data for Zevra Therapeutics' Notes Payables shows a peak YoY surged of 977.02% (in 2020) over the last 5 years.
  • Zevra Therapeutics' Notes Payables (Quarterly) stood at $1.9 million in 2016, then reached $3.3 million in 2018, then surged by 109.45% to $7.0 million in 2019, then surged by 881.24% to $65.9 million in 2020.
  • Its Notes Payables stands at $65.9 million for Q3 2020, versus $67.3 million for Q2 2020 and $68.6 million for Q1 2020.